‘Highest risk–highest benefit’ strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies

Detalles Bibliográficos
Autores principales: Annemans, Lieven, Packard, Chris J, Briggs, Andrew, Ray, Kausik K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Current Opinion
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6047410/
https://www.ncbi.nlm.nih.gov/pubmed/29236976
http://dx.doi.org/10.1093/eurheartj/ehx710
_version_ 1783339940278435840
author Annemans, Lieven
Packard, Chris J
Briggs, Andrew
Ray, Kausik K
author_facet Annemans, Lieven
Packard, Chris J
Briggs, Andrew
Ray, Kausik K
author_sort Annemans, Lieven
collection PubMed
description
format Online
Article
Text
id pubmed-6047410
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-60474102018-07-19 ‘Highest risk–highest benefit’ strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies Annemans, Lieven Packard, Chris J Briggs, Andrew Ray, Kausik K Eur Heart J Current Opinion Oxford University Press 2018-07-14 2017-12-11 /pmc/articles/PMC6047410/ /pubmed/29236976 http://dx.doi.org/10.1093/eurheartj/ehx710 Text en © The Author(s) 2017. Published by Oxford University Press on behalf of the European Society of Cardiology http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Current Opinion
Annemans, Lieven
Packard, Chris J
Briggs, Andrew
Ray, Kausik K
‘Highest risk–highest benefit’ strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies
title ‘Highest risk–highest benefit’ strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies
title_full ‘Highest risk–highest benefit’ strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies
title_fullStr ‘Highest risk–highest benefit’ strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies
title_full_unstemmed ‘Highest risk–highest benefit’ strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies
title_short ‘Highest risk–highest benefit’ strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies
title_sort ‘highest risk–highest benefit’ strategy: a pragmatic, cost-effective approach to targeting use of pcsk9 inhibitor therapies
topic Current Opinion
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6047410/
https://www.ncbi.nlm.nih.gov/pubmed/29236976
http://dx.doi.org/10.1093/eurheartj/ehx710
work_keys_str_mv AT annemanslieven highestriskhighestbenefitstrategyapragmaticcosteffectiveapproachtotargetinguseofpcsk9inhibitortherapies
AT packardchrisj highestriskhighestbenefitstrategyapragmaticcosteffectiveapproachtotargetinguseofpcsk9inhibitortherapies
AT briggsandrew highestriskhighestbenefitstrategyapragmaticcosteffectiveapproachtotargetinguseofpcsk9inhibitortherapies
AT raykausikk highestriskhighestbenefitstrategyapragmaticcosteffectiveapproachtotargetinguseofpcsk9inhibitortherapies

Ejemplares similares